Email updates

Keep up to date with the latest news and content from Retrovirology and BioMed Central.

This article is part of the supplement: AIDS Vaccine 2012

Open Access Poster presentation

Design of epitope-specific probes for sera analysis and antibody isolation

I Georgiev1*, P Acharya1, SD Schmidt1, Y Li2, D Wycuff3, G Ofek1, N Doria-Rose1, TS Luongo1, Y Yang1, T Zhou1, BR Donald4, JR Mascola1 and PD Kwong1

  • * Corresponding author: I Georgiev

Author Affiliations

1 Vaccine Research Center/NIAID/NIH, Bethesda, MD, USA

2 The Scripps Research Institute, La Jolla, CA, USA

3 National Institutes of Health, Bethesda, MD, USA

4 Duke University, Durham, NC, USA

For all author emails, please log on.

Retrovirology 2012, 9(Suppl 2):P50  doi:10.1186/1742-4690-9-S2-P50

The electronic version of this article is the complete one and can be found online at: http://www.retrovirology.com/content/9/S2/P50


Published:13 September 2012

© 2012 Georgiev et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background

The design of gp120 monomeric probes with modified antigenic profiles that are specific for a target epitope has been successfully used for the isolation of broadly neutralizing HIV-1 antibodies. Existing probes, however, do not possess sufficient specificity and can bind antibodies with undesired properties (e.g., weakly neutralizing antibodies targeting an overlapping epitope). To achieve improved epitope specificity, positive and negative design stages can be incorporated into the probe design process.

Methods

Here, we apply a combination of structure- and sequence-based methods for improving the epitope specificity of gp120 monomeric probes. Specifically, structure-based redesign using the OSPREY protein design software suite was used to predict gp120 knock-out mutations for selected antibodies. Additionally, using a sequence-based mutual information approach, knock-out mutations were designed by identifying gp120 residues that are predicted to associate with neutralization resistance for a given antibody.

Results

Using stabilized (Ds12F123) and resurfaced stabilized (RSC3) HXB2 gp120 cores as templates, we designed a set of mutants with improved epitope specificity. In particular, RSC3 (a prototypic probe previously used for the isolation of VRC01 and other CD4-binding-site antibodies) was redesigned to specifically bind CD4-binding-site antibodies that are broadly neutralizing (VRC01, VRC-PG04: positive design) but not moderately/weakly neutralizing (b12, b13, HJ16: negative design). Additionally, CD4i-specific probes were designed by introducing mutations that destabilize binding to the entire class of CD4-binding-site antibodies (negative design), while retaining binding to CD4i antibodies (positive design). The desired epitope specificity of the redesigned probes was confirmed by ELISA binding. The probe design approach was further validated with knock-out mutations for a diverse set of antibodies, including PG9 and 2F5.

Conclusion

Probes with enhanced epitope specificity can select more precisely for antibodies with desired properties. A set of our redesigned probes are currently being utilized for the isolation of antibodies targeting different epitopes of interest on the HIV-1 Envelope.